Search Within

Hematologic Malignancies, Division of

  1. "Anita Kumar"
Formats
  1. Meeting Abstract (95)
  2. Journal Article (63)
  3. Review (7)
  4. Book Section (6)
  5. Research Letter (4)
  6. Correspondence (1)
  7. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (177)
  2. Department of Medicine (177)
  3. Lymphoma (177)
  4. Survivorship Research (100)
  5. Population Sciences Research Program (91)
  6. Executive Committee, Center for Hematologic Malignancies (71)

More Groups

People
  1. Anita Kumar (177)
  2. Andrew Zelenetz (121)
  3. Paul Hamlin (94)
  4. Alison Moskowitz (93)
  5. Ariela Noy (93)
  6. Steven Horwitz (87)

More People

Years
  1. 2025 (4)
  2. 2024 (16)
  3. 2023 (32)
  4. 2022 (12)
  5. 2021 (24)
  6. 2020 (17)

More Years

Publications
  1. Blood (67)
  2. Hematological Oncology (19)
  3. Journal of Clinical Oncology (12)
  4. Blood Advances (11)
  5. Haematologica (9)
  6. Leukemia and Lymphoma (7)

More Publications

Publishers
  1. American Society of Hematology (79)
  2. Wiley Blackwell (19)
  3. American Society of Clinical Oncology (12)
  4. Nature Publishing Group (10)
  5. Ferrata Storti Foundation (9)
  6. Taylor & Francis Group (8)

More Publishers

Results (177)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
    Journal Article

    Chong, E. A.; Penuel, E.; Napier, E. B.; Lundberg, R. K.; Budde, L. E.; Shadman, M.; Matasar, M. J.; Bartlett, N. L.; Flinn, I. W.; Bosch, F.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
    Journal Article

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Practice patterns inform patient-centered approaches for the integration of BTK inhibitors in frontline mantle cell lymphoma
    Meeting Abstract

    Graham, T.; Ackbarali, T.; Kumar, A.; Matasar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of novel therapies (NTs) on real-world (RW) clinical outcomes of patients (pts) with relapsed/refractory (RR) mantle-cell lymphoma (MCL) by race/ethnicity and TP53 mutation status
    Meeting Abstract

    Phillips, T. J.; Danilov, A. V.; Ruan, J.; Patel, K.; Kumar, A.; Wang, Y. C.; Maglinte, G. A.; Seymour, E.; Kamdar, M.
    Blood (2024)

    Fulltext@MSK | Save
  • Molecular features are associated with disease stage in diffuse large B-cell lymphoma and reveal heterogeneity in patient outcomes
    Meeting Abstract

    Uppal, M.; Gurumurthi, A.; Hamlin, P. A.; Falchi, L.; Horwitz, S.; Kumar, A.; Noy, A.; Lue, J. K.; Torka, P.; Arcila, M. E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Updated safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma
    Correspondence

    Gurumurthi, A.; Bantilan, K. S.; Hamlin, P. A.; Kumar, A.; Matasar, M.; Zhu, M.; Joseph, A.; Castro, A.; Biggar, E.; Salles, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save